Supp. Figure 1 : Kolmogorov-Smirnov test results ( A ) of randomly subsampled distributions of tumor neoantigen binding affinities compared to HBV antigens across 1,000 iterations. B) Distribution of test p-values strongly support the alternative hypothesis that tumor neoantigen cumulative distributions were significantly less than HBV distributions, indicating better average binding affinity scores are robust to subsampling.
Supp. Figure 2:
Tumor neoantigen burden is slightly but significantly positively correlated with patient TIL-burden, while HBV antigen load is not. Spearman correlations are presented for epitope group and TIL-burden associations.
Supp. Figure 3:
Kaplan-Meier survival curves between patients with and without neoepitope BLAST matches against the viral IEDB database for the A) lung and B) melanoma TCGA cohorts. Tumor mutational burdens for patients with viral neoantigen matches fall significantly below those with no matches in both the C) lung and, D) melanoma patient groups (two-tailed T-test). Differences in cytolytic activity (CYT) expression were found to be negligible for both the NSCLC and SCKM patients between those with and without IEDB matches ( E and F , respectively) (two-tailed T-test).
Supp. Figure 4
: Comparison of smith-waterman alignment score distributions for tumor neoepitopes to best matching viral epitopes from the TCGA lung and melanoma cohorts and the checkpoint treated patient cohorts used in Luksza et al . By Kolmogorov-Smirnov two-sided test, no significant difference between alignment score distributions was observed.
